SLS On Track To Clock Best Week In Over 4 Months: Retail Divided Between Stock Drop Or Multibagger Status Amid Upcoming Leukemia Trial Readout

• So far this week, SLS has gained nearly 30%, on track for its best week since the week ended Jan 2, if gains hold.
• SELLAS is advancing two key programs in AML.
• According to data from Koyfin, the two analysts covering Sellas rate it ‘Buy’ or higher.

Shares of Sellas Life Sciences Group Inc (SLS) closed up 25% on Wednesday, a day after the company said that its pivotal late-stage trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) is now just two events away from triggering a topline data readout.

As of May 11, 2026, 78 deaths had occurred in the study, called REGAL, the company said. The prespecified 80th event will trigger analysis and disclosure of results, the company said. SELLAS remains blinded to the data as the study is being conducted by a contract research organization.

So far this week, SLS has gained nearly 30%, on track for its best week since the week ended Jan 2, if gains hold. To December-end, the company reported that 72 out of the prespecified 80 patient deaths required to trigger the final analysis had occurred as of Dec. 26, 2025, sparking a rally.

According to data from Koyfin, the two analysts covering Sellas rate it ‘Buy’ or higher. The 12-month average price target on the stock is $10, representing a potential upside of about 53% from the stock’s closing price on Wednesday.

How Did Sellas Retail Traders React?

On Stocktwits, retail sentiment stayed within the ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels. According to platform data, retail chatter around SLS jumped nearly 500% over the past 24 hours and by about 400% over the past seven days.

A Stocktwits user opined that the shares of the company will drop once the data is announced.

Another user opined that the imminent trial results would be “transformational.”

A third user highlighted that Sellas has not one but two “blockbuster assets.” “...in no dimension, this dimension or alternative dimension should SLS be a single-digit stock &/or at this valuation this late into development,” they wrote.

“...we believe that the upcoming results, triggered by reaching the pre-specified 80th event, will be an important milestone for the Company,” Sellas CEO Angelos Stergiou said about the GPS trial outcome.

SELLAS is advancing two key programs in AML. In addition to the REGAL trial, the company has begun dosing patients in an 80-patient mid-stage trial of its experimental drug SLS009 in newly diagnosed, first-line AML patients.

SLS stock has gained over 350% over the past 12 months. 

Read More: Nvidia Stock Draws Attention As Culper Research Takes Short Position Over China Ties

For updates and corrections, email newsroom[at]stocktwits[dot]com.